Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT).

Key Points

• This research aims to evaluate the clinical benefits of everolimus as a maintenance therapy for advanced neuroendocrine neoplasms.
• Conducted a Phase II trial (MAVERIC) for everolimus use in patients with advanced GEP-NEN and LCNEC.
• Included patients previously treated with first-line chemotherapy.
• Monitored safety and effectiveness of everolimus treatment.
• Demonstrated encouraging clinical benefits of everolimus in metastatic GEP-NEN and LCNEC patients.
• Found toxicity levels consistent with known safety profiles for everolimus.
• Indicated the treatment was particularly effective in GEP-NEN patients.